The European Medicines Agency is concerned there could be a potential link between thyroid cancer and the use of glucagon-like peptide-1 (GLP-1) receptor agonists, which includes medicines containing Novo Nordisk’s semaglutide like Ozempic, Rybelsus and Wegovy.
The agency raised a safety signal last month over the class of drugs and requested more information from Novo Nordisk, AstraZeneca, Sanofi and Eli Lilly, Reuters reported today after a Danish media outlet first published the signal.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters